News

Ingevity's Leadership Change: New Interim CEO Appointed

Ingevity's Leadership Change: New Interim CEO Appointed

Ingevity Announces CEO Transition

Ingevity Corporation (NYSE: NGVT) has experienced a significant change in its leadership with John Fortson stepping down as president and chief executive officer. Following his departure, the company has entrusted board director Luis Fernandez-Moreno with the role of interim president and CEO while a search is underway for a permanent successor.

Leadership Changes at Ingevity

The board of directors expressed its gratitude to Fortson for his nine years of dedicated service leading Ingevity. Under his guidance, the company has transformed into a thriving standalone public entity with a strong presence in key international markets. Board chair Jean Blackwell conveyed her appreciation for Fortson’s contributions, emphasizing the company’s growth during his tenure.

Fortson, mentored by years of experience, reflected on his journey with Ingevity, stating his gratitude to the board for the opportunity to serve and wishing the company success in its future endeavors.

Currently, Fernandez-Moreno, who has been on Ingevity’s board since its spinoff in 2016, is eager to lead the company into its next chapter. He has emphasized the need to build upon the groundwork laid during Fortson's leadership and focus on enhancing customer service and business performance.

Fernandez-Moreno's Background

Fernandez-Moreno brings extensive experience in the specialty chemicals sector, having spent 40 years in leadership roles across several global businesses. He previously led Ashland Inc.'s Chemicals division, which was valued at $3.5 billion. His career includes significant positions at Arch Chemicals and Rohm & Haas, the latter of which was acquired by Dow Chemical. He is recognized for his capability to foster innovation and build successful teams.

His educational background includes a Bachelor of Science in chemical engineering from Universidad Iberoamericana in Mexico City and completion of the Wharton Management Certificate Program, making him well-equipped to steer Ingevity through its ongoing transformation.

Search for Permanent CEO Begins

The board of directors has already initiated a search for a permanent president and CEO and has engaged a reputed executive search firm to assist in finding the right candidate. This transition is part of Ingevity's strategic plan to ensure a seamless leadership handover and continued growth.

Upcoming Financial Release

As part of its ongoing commitment to transparency, Ingevity is set to release its third quarter earnings following the market close on a designated date. Investors and stakeholders can expect a live webcast discussion following the results to further elaborate on financial performance and expectations.

About Ingevity

Ingevity is dedicated to providing innovative products and technologies that aim to purify, protect, and enhance the environment. The company operates through three primary segments: Performance Materials, Advanced Polymer Technologies, and Performance Chemicals. Their diverse product range serves various demanding applications, from agriculture to automotive components, highlighting the commitment to sustainability and customer solutions.

Headquartered in North Charleston, South Carolina, Ingevity employs around 1,700 people and operates in 31 countries, reflecting its global focus and dedication to driving progress in specialty chemicals.

Frequently Asked Questions

Who is the new interim CEO of Ingevity?

The new interim CEO of Ingevity is Luis Fernandez-Moreno, who has served on the board of directors since the company's spinoff.

What prompted the leadership change at Ingevity?

John Fortson stepped down from his role as president and CEO, leading the board to appoint Fernandez-Moreno as interim CEO while a search for a permanent replacement begins.

How has Ingevity performed under John Fortson's leadership?

Under Fortson’s guidance, Ingevity evolved into a successful standalone public company and strengthened its presence in key global markets.

What is the focus of Ingevity’s business strategy?

Ingevity's business strategy focuses on purifying, protecting, and enhancing the world through innovative products in specialty chemicals and advanced materials.

When will Ingevity release its third quarter earnings?

Ingevity plans to release its third quarter 2024 earnings at the end of October, with further details provided during a live webcast.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 24

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading

Top 5 Most Recently Viewed Articles

Embla Medical hf Reports Strong Q2 2025 Financial Performance

Updated Category News Views 203

Embla Medical hf's Interim Report for Q2 2025 Announcement No. 33/2025 Interim Report Q2 2025 Embla Medical hf has recently published its interim report for the second quarter of 2025, revealing encouraging financial results. The organization remains committed to enhancing mobility solutions through innovative offerings in prosthetics and orthotics. Strong Sales Growth...

Continue Reading
Fly-E Group Faces Important Class Action Deadline for Investors

Updated Category News Views 185

Fly-E Group Update: Important Class Action Deadline Attention investors of Fly-E Group, Inc. If you purchased securities between July 15 and August 14, 2025, this is vital news for you. As we approach a crucial lead plaintiff deadline on November 10, 2025, the time to act is now. Understanding the Class Action The upcoming class action lawsuit revolves around Fly-E's...

Continue Reading
Royal Unibrew Posts Impressive Earnings Growth in Q3 2024

Updated Category News Views 173

Royal Unibrew's Remarkable Performance in Q3 2024 Royal Unibrew has demonstrated exceptional growth during the third quarter of 2024. The key highlights from this trading statement reveal a robust progression in organic volume and net revenue, paving the way for a bright future for the company. Strong Growth Metrics Organic Volume and Revenue Increases During Q3 2024,...

Continue Reading
Examining Medtronic PLC's Short Selling Trends and Insights

Updated Category News Views 184

Understanding Medtronic PLC's Short Interest Medtronic PLC (NYSE: MDT) has recently experienced a significant rise in its short interest as a percentage of float, currently at 17.56%. This increase signals a growing concern among investors, as the total number of shares sold short has reached 19.72 million, accounting for 1.54% of all available shares for trading. With...

Continue Reading
Palatin Technologies Announces Breakthrough in Obesity Management

Updated Category News Views 138

Positive Developments in Appetite Suppression Research Palatin Technologies, Inc. (NYSE American: PTN), a leading biopharmaceutical firm known for pioneering medications based on the melanocortin receptor system, has recently reported encouraging results concerning appetite suppression from its Phase 2 obesity study involving bremelanotide and tirzepatide. This...

Continue Reading